Science in Motion: Autumn and Sabrina’s Noteworthy Novartis Adventure

Science in Motion: Autumn and Sabrina’s Noteworthy Novartis Adventure
hajdola1

/by

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
arcticnovartis

 Ad hoc announcement pursuant to Art. 53 LR

/by